King Pharmaceuticals has made available Embeda (morphine sulfate and naltrexone HCl extended-release capsules), a long-acting opioid analgesic, for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Embeda is designed to reduce drug liking and euphoria when tampered with by crushing or chewing. However, the clinical significance of the degree of reduction in drug liking and euphoria reported in clinical studies has not yet been established.
Embeda is a C-II controlled substance. It is available in six fixed-dose combination capsules containing morphine sulfate and sequestered naltrexone HCl: 20mg/0.8mg, 30mg/1.2mg, 50mg/2mg, 60mg/2.4mg, 80mg/32mg, and 100mg/4mg.
For more information call (800) 776-3637 or visit www.embeda.com.